Showing posts with label Medicare. Show all posts
Showing posts with label Medicare. Show all posts
Saturday, July 2, 2022

SCOTUS on dialysis and DaVita

›
  The Supreme Court delivered a number of decisions recently, and the news coverage has rightly focused on the decisions that will increase ...
Monday, April 4, 2022

Transplant wait lists and patient finances

›
 Here's a disturbing commentary on how the regulation of transplant centers interacts with patient finances and the decision of who to p...
Tuesday, April 13, 2021

The complex economics of dialysis and insurance, in Freakonomics

›
 Freakonomics peeks under the rocks to see what crawls out: Is Dialysis a Test Case of Medicare for All? (Ep. 457)  by Stephen J. Dubner ...
Monday, January 11, 2021

Remembering the 116th Congress (it fixed Medicare coverage of immunosuppressive drugs for transplant patients)

›
  This won't be the most memorable thing about the Congress that adjourned in 2020, but it's something positive: up through the end ...
Tuesday, February 19, 2019

Payments for kidney disease in the U.S.

›
Medpage Today has the story: Kidney Disease Payment System Draws Medicare Scrutiny 'We do not think the state of kidney disease care...
Friday, August 15, 2014

Competition, Market Design, and Medicare Part D

›
The Congressional Budget Office (CBO) has a new report about Competition and the Cost of Medicare's Prescription Drug Program:  ...
Friday, July 19, 2013

Medicare's 3 year limit on post-transplant immunosuppressive drugs

›
A lot has been written about this, here's yet another story that puts a personal edge on a systematic problem and a big waste of taxpaye...
Saturday, March 2, 2013

Federal budgets and immunosuppressive drugs for transplant patients

›
One of the funny things about Medicare is that it pays for dialysis, and for kidney transplants so that patients won't need dialysis, bu...
Tuesday, September 18, 2012

Cramton on the Medicare auction

›
Market design can be frustrating: Peter reports from the front line. Medicare auction gets failing grade at Congressional hearing
Thursday, February 16, 2012

Penny wise and pound foolish: now in the NEJM

›
It's truer than ever that in the United States we have a foolish Medicare policy of only paying for three years of anti-rejection drugs ...